Department of Medical Oncology & Therapeutics Research, City of Hope, 1500 East Duarte Rd, Duarte, CA 91010, USA.
LIXTE Biotechnology, Inc. 680 E Colorado Blvd, Suite 180, Pasadena, CA 91101, USA.
Bioanalysis. 2023 Sep;15(17):1095-1107. doi: 10.4155/bio-2023-0078. Epub 2023 Aug 16.
We have developed and validated a novel LC-MS/MS method for the simultaneous quantification of LB-100 and its active metabolite, endothall, in human plasma following solid-phase extraction. LB-105 and endothall-D6 were used as internal standards. Chromatographic separation was achieved on a Hypercarb™ column using 5 mM (NH)CO and 30:70 (v/v) 100 mM (NH)CO:acetonitrile as mobile phases. Detection was performed via positive electrospray ionization mode with multiple reaction monitoring. The assay exhibited linearity in the concentration range of 2.5-500 ng/ml for both analytes. Intra- and inter-assay precision and accuracy were within ±11%. LB-100 and endothall recoveries were 78.7 and 86.7%, respectively. The validated LC-MS/MS method enabled the accurate measurement of LB-100 and endothall in patient samples from an ongoing clinical trial (NCT04560972).
我们开发并验证了一种新的 LC-MS/MS 方法，可用于固相萃取后同时定量人血浆中的 LB-100 及其活性代谢物草甘膦。LB-105 和草甘膦-D6 用作内标。采用 Hypercarb™柱，以 5 mM（NH）CO 和 30:70（v/v）100 mM（NH）CO：乙腈作为流动相进行色谱分离。采用正电喷雾电离模式，以多反应监测进行检测。该分析方法对两种分析物的浓度范围为 2.5-500 ng/ml 时呈线性。日内和日间精密度和准确度均在±11%范围内。LB-100 和草甘膦的回收率分别为 78.7%和 86.7%。验证后的 LC-MS/MS 方法可用于准确测量正在进行的临床试验（NCT04560972）中患者样本中的 LB-100 和草甘膦。
